The Journal of
Clinical Psychiatry

Neurodevelopmental

Brainstorms March 15, 2010

Mechanism of Action of α2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms

Stephen M. Stahl, MD, PhD

J Clin Psychiatry 2010;71(3):223-224

Article Abstract

Mechanism of Action of α_2A-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder With or Without Oppositional Symptoms

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

Download Free PDF

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue